UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Lower Mortality in Magnet Hospitals

Medical care, 2013-05, Vol.51 (5), p.382-388

2013

Link zum Volltext

Verfügbarkeit prüfen

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

Blood, 2010-12, Vol.116 (23), p.4934-4937

2010

Link zum Volltext

Verfügbarkeit prüfen

Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres

British journal of haematology, 2011-05, Vol.153 (3), p.358-363

2011

Link zum Volltext

Verfügbarkeit prüfen

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8002-8002

2023

Link zum Volltext

Verfügbarkeit prüfen

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

British journal of haematology, 2009-07, Vol.146 (2), p.158-163

2009

Link zum Volltext

Verfügbarkeit prüfen

POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S226-S226

2023

Link zum Volltext

Verfügbarkeit prüfen

P-030 First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S49-S50

2023

Link zum Volltext

Verfügbarkeit prüfen

MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S478-S479

2023

Link zum Volltext

Verfügbarkeit prüfen

Pilot Trial of Homebound Stem Cell Transplantation at Memorial Sloan Kettering Cancer Center

Biology of blood and marrow transplantation, 2016-03, Vol.22 (3), p.S137-S137

2016

Link zum Volltext

Verfügbarkeit prüfen

Progress Towards Value in Healthcare: Implementation of Time-Driven Activity-Based Costing (TDABC) in Hematopoietic Stem Cell Transplantation

Biology of blood and marrow transplantation, 2016-03, Vol.22 (3), p.S87-S87

2016

Link zum Volltext

Verfügbarkeit prüfen

High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging

British journal of haematology, 2010-03, Vol.148 (6), p.890-897

2010

Link zum Volltext

Verfügbarkeit prüfen

Pertussis Immunity and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after Autologous Peripheral Blood Stem Cell Transplantation

Biology of blood and marrow transplantation, 2009-12, Vol.15 (12), p.1538-1542

2009

Link zum Volltext

Verfügbarkeit prüfen

High Number of Successful Mobilizations Associated with the Use of Plerixafor and Colony Stimulating Factors In Patients with Multiple Myeloma (MM) and Lymphoma Treated at Memorial Sloan-Kettering Cancer Center

Blood, 2010-11, Vol.116 (21), p.2263-2263

2010

Link zum Volltext

Verfügbarkeit prüfen

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers

Blood, 2009-11, Vol.114 (22), p.3413-3413

2009

Link zum Volltext

Verfügbarkeit prüfen

The effects of changes in the hospital nursing workforce and practice environment on the outcomes of surgical oncology patients: A two-stage panel study

Vanak, Jill Marie

2014

Link zum Volltext
ProQuest

Nonphysician Health Professionals

International Encyclopedia of the Social & Behavioral Sciences, 2015, Vol.16, p.907-913

Second Edition, 2015

Link zum Volltext

Verfügbarkeit prüfen

Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant

Blood, 2009-11, Vol.114 (22), p.720-720

2009

Link zum Volltext

Verfügbarkeit prüfen

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Blood, 2008-11, Vol.112 (11), p.776-776

2008

Link zum Volltext

Verfügbarkeit prüfen

Establishing a Post-Hematopoietic Stem Cell Transplant Immunization Clinic: A Single Institution Experience

Biology of blood and marrow transplantation, 2013-02, Vol.19 (2), p.S354-S354

2013

Link zum Volltext

Verfügbarkeit prüfen

Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

Blood, 2008-11, Vol.112 (11), p.775-775

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(19)

Publikationsform

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Blood
(6)
Biology Of Blood And Marrow Transplantation
(4)
British Journal Of Haematology
(3)
Clinical Lymphoma, Myeloma And Leukemia
(3)
Hemasphere
(1)
Journal Of Clinical Oncology
(1)
Medical Care
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lower Mortality in Magnet Hospitals

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

S190: FIRST RESULTS FROM THE REDIRECTT‐1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

P-030 First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Pilot Trial of Homebound Stem Cell Transplantation at Memorial Sloan Kettering Cancer Center

Progress Towards Value in Healthcare: Implementation of Time-Driven Activity-Based Costing (TDABC) in Hematopoietic Stem Cell Transplantation

High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging

Pertussis Immunity and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after Autologous Peripheral Blood Stem Cell Transplantation

High Number of Successful Mobilizations Associated with the Use of Plerixafor and Colony Stimulating Factors In Patients with Multiple Myeloma (MM) and Lymphoma Treated at Memorial Sloan-Kettering Cancer Center

Initial Remission Duration of Less Than 1 Year Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose Therapy and Autologous Stem Cell Transplant: Results of a Combined Analysis From Two Large Transplant Centers

The effects of changes in the hospital nursing workforce and practice environment on the outcomes of surgical oncology patients: A two-stage panel study

Nonphysician Health Professionals

Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Establishing a Post-Hematopoietic Stem Cell Transplant Immunization Clinic: A Single Institution Experience

Normalization of FDG-PET Pre-ASCT with Additional Non-Cross Resistant Chemotherapy Improves EFS in Patients with Relapsed and Primary Refractory Hodgkin Lymphoma-Memorial Sloan Kettering Protocol 04-047

Suchergebnisse filtern